Literature DB >> 33311439

Cationic nanocarriers as potent adjuvants for recombinant S-RBD vaccine of SARS-CoV-2.

Hong Lei1, Aqu Alu1, Jingyun Yang1, Cai He1, Weiqi Hong1, Zesheng Cheng1, Li Yang1, Jiong Li1, Zhenling Wang1, Wei Wang1, Guangwen Lu1,2, Xiawei Wei3.   

Abstract

Entities:  

Year:  2020        PMID： 33311439     DOI： 10.1038/s41392-020-00434-x

Source DB:  PubMed          Journal:  Signal Transduct Target Ther        ISSN： 2059-3635


× No keyword cloud information.
  5 in total

1.  Designing of disruptor molecules to restrain the protein-protein interaction network of VANG1/SCRIB/NOS1AP using fragment-based drug discovery techniques.

Authors:  Suchandra Roy Acharyya; Plaboni Sen; Thirukumaran Kandasamy; Siddhartha Sankar Ghosh
Journal:  Mol Divers       Date:  2022-06-01       Impact factor: 2.943

2.  Intranasal administration of a recombinant RBD vaccine induces long-term immunity against Omicron-included SARS-CoV-2 variants.

Authors:  Hong Lei; Aqu Alu; Jingyun Yang; Wenyan Ren; Cai He; Tianxia Lan; Xuemei He; Li Yang; Jiong Li; Zhenling Wang; Xiangrong Song; Wei Wang; Guangwen Lu; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2022-05-17

3.  A Perspective on the Roles of Adjuvants in Developing Highly Potent COVID-19 Vaccines.

Authors:  Naru Zhang; Kangchen Li; Zezhong Liu; Kutty Selva Nandakumar; Shibo Jiang
Journal:  Viruses       Date:  2022-02-14       Impact factor: 5.048

Review 4.  Intravenously Infused Stem Cells for Cancer Treatment.

Authors:  Alison R Mercer-Smith; Ingrid A Findlay; Hunter N Bomba; Shawn D Hingtgen
Journal:  Stem Cell Rev Rep       Date:  2021-06-17       Impact factor: 5.739

Review 5.  Nasal Nanovaccines for SARS-CoV-2 to Address COVID-19.

Authors:  Jialu Huang; Yubo Ding; Jingwei Yao; Minghui Zhang; Yu Zhang; Zhuoyi Xie; Jianhong Zuo
Journal:  Vaccines (Basel)       Date:  2022-03-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.